MedTrace Logo

Randomized Evaluation of Anagliptin Versus Sitagliptin On Low-density lipoproteiN Cholesterol in Diabetes Trial

NCT02330406 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 353

Last updated 2019-08-28

No results posted yet for this study

Summary

The purpose of this study is to determine whether Anagliptin or Sitagliptin are effective in reducing the low-density lipoprotein cholesterol in patients with type 2 diabetes and cardiovascular risk factors on statin.

Conditions

  • Dipeptidyl-Peptidase 4 Inhibitors
  • LDL Cholesterol
  • Glycosylated Hemoglobin
  • Diabetes Mellitus
  • Coronary Disease

Interventions

DRUG

Anagliptin

Suiny 100 mg

DRUG

Sitagliptin

Januvia 50 mg Glactiv 50 mg

Sponsors & Collaborators

  • Institute for Clinical Effectiveness, Japan

    lead OTHER

Principal Investigators

  • Shinichiro Ueda, MD, PhD · Professor of Medicine, Department of Clinical Pharmacology & Therapeutics, University of the Ryukyus

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-04-30
Primary Completion
2018-01-31
Completion
2019-03-31

Countries

  • Japan

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02330406 on ClinicalTrials.gov